BGM Group (BGM) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed BGM Group (BGM) over the past year, gaining 20.4% versus a loss of 96.6%. Over five years, CRDL leads with a -66.9% price change compared with -98.3% for BGM. Cardiol Therapeutics is the larger company by market cap ($158.0 million vs $133.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | CRDL |
|---|---|---|
| Share price | $9.96 | $1.30 |
| Market cap | $133.01M | $157.97M |
| 1-day change | +6.07% | -1.52% |
| YTD return | -91.00% | +36.27% |
| 1-year return | -96.64% | +20.37% |
| 5-year return | -98.32% | -66.92% |
| EPS (TTM) | $-4.80 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $2.34 |
| 52-week low | $6.45 | $0.88 |
| Distance from 52-week high | -96.71% | -44.44% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +543.08% |
| Average volume | 6.09K | 1.44M |
| Shares outstanding | 12.69M | 121.51M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed BGM by 117.0 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
BGM vs CRDL FAQ
Which is bigger, BGM Group or Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $157.97M compared with $133.01M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or CRDL?
CRDL returned +20.37% over the past 12 months, compared with -96.64% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Cardiol Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BGM Group and Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics.